Artiflex toric foldable phakic intraocular lens for the correction of moderate to high myopia: five year follow-up results

Session Details

Session Title: Presented Poster Session: Refractive Surgery New Techniques/Instrumentation/Devices I

Venue: Poster Village: Pod 2

First Author: : I.Carneiro PORTUGAL

Co Author(s): :    A. Marta   M. Lume   M. Pinto                 

Abstract Details

Purpose:

To evaluate the long-term efficacy, predictability and safety of the foldable Artiflex toric phakic intraocular lens (pIOL; Ophtec) for the correction of myopia with astigmatism.

Setting:

Department of Ophthalmology of a tertiary referral center in Oporto, Portugal – Centro Hospitalar Universitário do Porto.

Methods:

Retrospective study of 90 eyes of 45 patients implanted with an Artiflex toric pIOL. Mean implanted spherical and cylindrical powers was -8 diopters (D) (range from -2,25 to -14,5 D) and -2 D (range from -1 to -4 D), respectively. Total follow-up was 5 years. Outcome parameters included uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), intraocular pressure, endothelial cell density (ECD) and complications. Comparisons were made between preoperative clinical data and the clinical data at each year after surgery.

Results:

The mean spherical equivalent after 5 years was -0,05 ± 0,28 D, with no significant change in mean SE between each year. At 5 years, 93% of eyes had a UCVA of >20/40 and postoperative UCVA was equal to or better than preoperative BCVA in 85,3 % of eyes. Five percent of eyes gained 1 or more Snellen lines of BSCVA, at 5 years. In 3 of eyes the remaining cylinder was -0,5 D. The mean endothelial cell loss was 285 at 5 year. The mean intraocular pressure remained stable at 14 ± 2 mmHg and few complications were identified.

Conclusions:

The Artiflex toric pIOL effectively and safely corrects myopia in the long term, with stable and predictable visual results after 5 years, when strict inclusion criteria are applied. There was no significant loss of corneal endothelial cells and very few complications were reported.

Financial Disclosure:

None